← Feed

u/Equal_Dragonfruit_39

4 theses · first seen Sep 4, 2026
WindowThesesResolvedWinsWin rateAvg returnMedian return
1d——————
3d——————
1w——————
1m——————
3m——————
6m——————
1y——————

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$PSTVr/pennystocksTechnical Analysisbullish
u/Equal_Dragonfruit_39 · 393d ago3 prior · awaiting results

$PSTV Valuation [Part 2]

PSTV operates a diagnostics business (CNSide test) and Rx pipeline (REYOBIQ) for leptomeningeal metastatic cancers. Using conservative revenue assumptions and peer sales multiples (3-8x), the author values the company at $1.8B–$45.2B depending on scenario, with current market cap at ~$81M implying the stock is significantly undervalued. Near-term catalysts include UHC paid claims signals, Q3 earnings, and additional payer coverage announcements.

original post →
$PSTVr/pennystocksDDbullish
u/Equal_Dragonfruit_39 · 395d ago3 prior · awaiting results
Long PSTV

Why UNH partnered with $PSTV (and why all other payers will too) [PART 1]

UnitedHealthcare's partnership to cover CNSide's leptomeningeal disease assay creates a competitive domino effect: other major payers (Blues, Aetna, Cigna, Humana, HCSC) will likely follow within 6-18 months due to risk-adjustment economics (40k/year uplift per case vs. 3k test cost) and competitive pressure. PSTV is the sole provider of this test, positioning it to capture massive TAM expansion across Medicare Advantage and ACA exchange markets.

original post →
$ATCHr/pennystocksDDbullish
u/Equal_Dragonfruit_39 · 403d ago3 prior · awaiting results

$ATCH – The Hidden Value Lever

AtlasClear's stock loan business is rapidly growing (15% of revenue in July, outperforming in August) with 65% margins versus 8.7% legacy margins. The September 29 10-K will understate the true forward earnings power since stock loan acceleration began only in late June; under reasonable scenarios (15-20% stock loan penetration), net income could double to $2.6-3.2M, implying $2-5/share over 12 months depending on margin assumptions and debt paydown.

At post $0.83Now $0.14-83.2% since posted3m ago
1d-4.2%
3d-4.2%
1w-42.7%
1m-55.0%
3m-67.3%
6m-75.6%
1y-77.2%
original post →
$ATCHr/pennystocksTechnical Analysisbearish
u/Equal_Dragonfruit_39 · 413d ago3 prior · awaiting results
“Bought at $0.38 and sold at $0.90 this morning”

$ATCH – Dilution Risk

AtlasClear faces ongoing dilution risk from ~28M shares of convertible debt that noteholders can convert at discounts to VWAP and immediately sell into strength. Share count has more than doubled in 6 weeks, with fully diluted risk reaching ~50M shares; until the toxic financing structure is resolved, each price spike creates liquidity events for noteholder conversions that suppress long-term returns.

At post $0.99Now $0.14-86.0% since posted3m ago
1d-12.6%
3d+18.2%
1w-42.0%
1m-59.0%
3m-66.7%
6m-78.8%
1y-81.9%
original post →

End of results.